Can Autoship and Health Growth Support Chewy Stock's Valuation?

Chewy's fiscal Q2 2026 adjusted EBITDA rose 23.7% year over year to $226.7 million, lifting margin 90bps to 6.8%, while Autoship sales grew 9.3% and represented 84.6% of net sales. Vet Care revenue grew at a triple-digit rate, but more than $25 million of discrete and timing-related benefits—including tariff refunds and rebates—accounted for essentially all EBITDA outperformance versus expectations. Adjusted EPS was broadly in line at $0.36, while soft discretionary pet-product demand, competition, elevated stock compensation costs, and a Zacks Rank #4 (Sell) temper the operating progress.

Analysis

The key underwriting question is not top-line durability but whether CHWY can convert its installed customer base into normalized margin expansion after stripping out transitory items. The reported EBITDA beat appears largely non-recurring, so consensus models should be stress-tested against a roughly 70-80bp lower near-term margin run-rate if those benefits do not repeat. With discretionary mix softening, incremental advertising and health gross profit must outpace fulfillment, labor and stock-compensation drag to support an earnings rerating over the next 1-3 quarters.

Chewy's health build-out is strategically more important than its current revenue contribution: veterinary relationships can reduce customer churn, create prescription/insurance-adjacent monetization, and make price comparison with AMZN less relevant. But it is capital- and execution-intensive; clinic ramp losses, veterinarian scarcity, and telehealth regulation could delay breakeven for 6-18 months. WOOF is the more exposed competitor if Chewy scales a credible omnichannel vet network, while FRPT could benefit indirectly if health-led engagement supports premium nutrition adoption, although weak treat demand argues against extrapolating that outcome.

Contrarian view: recurring delivery penetration makes revenue less economically discretionary than the weak non-core category data imply, so a modest deceleration may not warrant a broad multiple de-rating. Conversely, the apparent low PEG is not actionable without confidence in estimate quality: declining revisions and weak momentum often precede a reset in margin assumptions. The next earnings call is the decisive catalyst—investors need proof that ex-items EBITDA margin holds above approximately 6.5% while customer monetization continues to rise.

Key Decisions for Investors

• Maintain CHWY as a watch-list long rather than initiating ahead of the next print. Enter only if management guides to sustainable ex-items EBITDA margin of at least 6.5% and consensus FY EBITDA estimates stabilize; target a 15-20% rerating over 3-6 months, with a stop on margin guidance below 6.0% or renewed negative EPS revisions.
• Express relative competitive risk via long CHWY / short WOOF over the next 6-12 months, sized modestly. Chewy's digital scale and health cross-sell can pressure WOOF's customer acquisition and clinic economics; cover if WOOF demonstrates sustained positive comparable sales and material EBITDA improvement, or if Chewy's health losses accelerate.
• Avoid using FRPT as a direct sympathy long. Premium pet-food exposure remains vulnerable to consumer trade-down; revisit only after category data show sequential recovery in discretionary pet spending and FRPT confirms volume-led rather than price-led growth.
• At the next CHWY results, isolate advertising revenue, health contribution margin, clinic ramp costs, and stock-based-compensation trajectory. A repeat of beat quality driven by rebates, tariff recoveries, or timing benefits is a short-term de-risking signal rather than confirmation of structural operating leverage.